Evaluation of the time dependent variability of the anti-factor Xa activity of therapeutic nadroparin in critically ill patients: a pharmacokinetic study
Recruiting
- Conditions
- Critically ill patients
- Registration Number
- NL-OMON20466
- Lead Sponsor
- Martini Ziekenhuis, Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 25
Inclusion Criteria
(1) Admitted to the Intensive Care with nadroparin in therapeutic dose (1-daily or 2-daily)
(2) Age = 18 years
Exclusion Criteria
(1) Pregnancy
(2) Requiring hemodialysis (HD) or Continuous Veno-Venous Hemofiltration (CVVH)
(3) Treated with a DOAC, unfractionated heparin, another LMWH, or a GP IIb / IIIa receptor antagonist 72hours to 0 hours before the first bloodsample is drawn or during bloodsampling.
(4) Participation in another study
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of inadequate estimated peak anti-factor-Xa levels after therapeutic nadroparin in a general intensive care unit population
- Secondary Outcome Measures
Name Time Method To evaluate the pharmacokinetics of therapeutic nadroparin in a general intensive care unit population by measuring anti-factor Xa levels.